Pharmacoeconomic evaluation of new treatments: Efficacy versus effectiveness studies?

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Bombardier, C ^b   Maetzel, A ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b INSTITUTE FOR WORK AND HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC AGENT; NEW DRUG;

ARTHRITIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH ECONOMICS; HUMAN; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0032732055     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2008.i82     Document Type: Review

References (25)

1. Canadian Coordinating Office for Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa, CCOHTA, 1997.
2. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits advisory committee: including submission involving economic analyses. Canberra, Australian Government Publishing Service, 1995..
3. Fryback DG. QALYs, HYEs, and the loss of innocence [editorial; comment]. Med Decis Making 1993;13:271-2.
4. Richardson J. Cost utility analysis: what should be measured? Soc Sci Med 1994;39:7-21.
5. Cairns JA. Valuing future benefits. Health Econ 1994;3: 221-9.
6. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993;31:403-18.
7. Redelmeier DA, Heller DN. Time preference in medical decision making and cost-effectiveness analysis [see comments]. Med Decis Making 1993;13:212-17.
8. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;32:150-63.
9. Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3:309-19.
10. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine [see comments]. JAMA 1996;276:1172-7.
11. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine [see comments]. JAMA 1996;276:1339-41.
12. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-68.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine [see comments]. JAMA 1996;276: 1253-8.
14. Anonymous. Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology [see comments]. Ann Intern Med 1995;123:61-70.
15. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313: 275-83.
16. Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation [editorial; comment] [see comments]. Ann Intern Med 1995;123:59-60.
17. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies [see comments]. N Engl J Med 1991;324:1362-5.
18. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses [editorial] [see comments]. N Engl J Med 1994;331:669-70.
19. Mason J, Drummond M. Reporting guidelines for economic studies [editorial]. Health Econ 1995;4:85-94.
20. Drummond MF, Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assess Health Care 1991;7:561-73.
21. O'Brien B. Economic evaluation of pharmaceutical. Frankenstein's monster or vampire of trials? Med Care 1996;34: DS99-108.
22. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal anti-inflammatory drugs [see comments]. Arthritis Rheum 1998;41:16-25.
23. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis. Br J Rheumatol 1998;37:1102-9.
24. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in clinical trials. J Chron Dis 1967;20:637-48.
25. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 1983;99:544-50.